Animal models are established, important tools for preclinical safety and efficacy testing. Companies are advancing more “humanized” models to better reflect human responses, while at the same time ...

Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...

Oral MYC condensate modulator drives tumor regression and stasis in preclinical modelsDisruption of MYC condensates enables targeted inhibition ...

Merck KGaA plans to replace most animal testing in drug development with advanced preclinical models over the next decade, aligning with a global regulatory push toward human-centric methods. The move ...

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in ...

Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...

Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related ...

SAN DIEGO , CA, UNITED STATES, April 17, 2026 /EINPresswire.com/ -- In today’s life sciences landscape, the journey ...